e-Article
Etamycin as a Novel Mycobacterium abscessus Inhibitor
Document Type
Dissertation/ Thesis
Author
Source
Subject
Language
English
Abstract
Mycobacterium abscessus 는 결핵균과 같은 속의 균으로서 많은 항생제 내성을 지니고 있으며 M. abscessus의 치료제로 알려져 있는 amikacin, cefoxitin, clarithromycin에 대해서도 쉽게 내성이 생기는 등의 문제로 새로운 약물의 개발이 시급하다. 이에 본연구에서는 M. abscessus에 우수한 활성을 보이는 etamycin이란 약물을 한국 화합물은행 라이브러리로부터 약물 스크리닝을 통해 후보 물질로 선별해내었고 생체외 실험을 통해 M. abscessus의 wild-type과 3개의 subspecies 및 임상 분리 균주들에서 활성을 확인하였다. 또한 세포에대한 etamycin의 독성 및 활성을 확인 한 결과 다양한 세포들에 대한 독성이 확인되지 않았으며, 세포내 감염을 통한 M. abscessus에 대한 etamycin의 활성 실험에서도 효과적으로 균의 생장을 억제시키는 것을 확인하였다. 마지막으로 생체 모델인 제브라피쉬를 이용하여 M. abscessus에 대한 생체내 약효 활성 실험을 진행하였을 때에도 현재 알려져 있는 M. abscessus의 치료제인 clarithromycin 보다 더욱 좋은 효능을 보이는 것을 확인하였습니다. 따라서 저희는 etamycin이 M. abscessus의 새로운 항생제로서 사용가능 하다는 결론을 내렸습니다.
Mycobacterium abscessus is a bacteria of the same genus as Mycobacterium tuberculosis, and has many antibiotic resistance. In addition, the development of new drugs is urgently due to problems such as easily becoming resistant to amikacin, cefoxitin, clarithromycin known as the treatment of Mycobacterium abscessus. In this research, etamycin has therefore been isolated from Korea compound bank library as a candidate substance through screening, showing an excellent action against Mycobacterium abscessus. Through in vitro experiments, wild-type subspecies and three subspecies of Mycobacterium abscessus, as well as extraclinical experiments were investigated. The activity was confirmed here through separation. Furthermore, as a result of evidence of etamycin toxicity and activity to cells, various cells have not been toxic and etamycin activity with intracellular infections have been reported to inhibit bacterial development. Finally, it has been reported that the latest well known treatment of Mycobacterium abscessus has shown better effectiveness than clarithromycin, even when performing an in-vive drug activity test using zebrafish, a biological model. We concluded that etamycin could be used as a modern Mycobacterium abscessus antibiotic.
Mycobacterium abscessus is a bacteria of the same genus as Mycobacterium tuberculosis, and has many antibiotic resistance. In addition, the development of new drugs is urgently due to problems such as easily becoming resistant to amikacin, cefoxitin, clarithromycin known as the treatment of Mycobacterium abscessus. In this research, etamycin has therefore been isolated from Korea compound bank library as a candidate substance through screening, showing an excellent action against Mycobacterium abscessus. Through in vitro experiments, wild-type subspecies and three subspecies of Mycobacterium abscessus, as well as extraclinical experiments were investigated. The activity was confirmed here through separation. Furthermore, as a result of evidence of etamycin toxicity and activity to cells, various cells have not been toxic and etamycin activity with intracellular infections have been reported to inhibit bacterial development. Finally, it has been reported that the latest well known treatment of Mycobacterium abscessus has shown better effectiveness than clarithromycin, even when performing an in-vive drug activity test using zebrafish, a biological model. We concluded that etamycin could be used as a modern Mycobacterium abscessus antibiotic.